Sofosbuvir / velpatasvir is up for review. This morning the Canadian Agency for Drugs and Technologies in Health (CADTH) sent out notice that they are currently seeking patient group input for sofosbuvir / velpatasvir. Sofosbuvir / velpatasvir is an all-pill, short-course, interferon-free treatment for those with chronic hepatitis C, genotype 1, 2, 4, 5, or 6.

Please keep your eyes open for a blog post with more information about sofosbuvir / velpatasvir and a link to PHCN’s patient input survey. They will be finalized and sent out in the next few days.

About Patient Group Input Reports Requested by CADTH

Within the Canadian drug approval process, Health Canada first evaluates a drug’s safety, clinical effectiveness, and its manufacturing process. The Common Drug Review (CDR) by CADTH then assesses the treatment’s clinical and cost-effectiveness as it compares to other treatments.

During Common Drug Reviews, CADTH requests patient input reports. These patient input reports help ensure that health outcomes and issues important to patients are incorporated into the Common Drug Review process in a formal and meaningful way.

They help ensure that patients and their loved ones are a part of the drug review process!

Please email or visit the Hepatitis C Treatment Information Project for more information about sofosbuvir / velpatasvir or any other hep C treatment.